Zacks Research Downgrades UCB (OTCMKTS:UCBJY) to Hold

UCB (OTCMKTS:UCBJY) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Wednesday, Zacks reports.

A number of other analysts also recently weighed in on the stock. Barclays downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Jefferies Financial Group upgraded UCB from a “moderate sell” rating to a “hold” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

UCB Trading Up 1.4%

OTCMKTS:UCBJY opened at $119.73 on Wednesday. The stock’s 50 day simple moving average is $128.90 and its two-hundred day simple moving average is $140.10. UCB has a 1 year low of $114.53 and a 1 year high of $168.76. The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for people living with severe neurological and immunological diseases. The company operates internationally, serving patients and healthcare providers across North America, Europe and other global markets.

Its neurology portfolio includes treatments such as Keppra and Briviact for epilepsy, Vimpat for partial-onset seizures and Fintepla for certain severe seizure disorders. In immunology, UCB markets Cimzia for conditions including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and Crohn’s disease, as well as Bimzelx for several inflammatory skin and joint conditions.

UCB traces its origins to 1928, when it was established in Belgium as Union Chimique Belge.